Top

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Published in:

Open Access 01-12-2021 | Escitalopram | Research

Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India

Authors: Tatiyana Mandal, Laxminarayana Kurady Bairy, Podila Satya Venkata Narasimha Sharma, Vijaya Lakshmi Valaparla

Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Issue 1/2021

Abstract

Background

Antidepressant response is a complex trait influenced by clinical, demographic and genetic factors.

Objectives

To explore the influences of baseline depression severity, gender and type of depressive episode on efficacy and safety of escitalopram (10–20 mg/day) in South Indian patients with major depressive disorder (MDD).

Methods

The study was conducted on 18–65-year-old patients (n = 151) suffering from a first or recurrent episode of MDD with a 17-item Hamilton Depression Rating Scale (HDRS-17) score of ≥ 18 at baseline. Efficacy assessments were done using HDRS-17, Montgomery-Asberg Depression Rating Scale (MADRS), and Clinical Global Impression (CGI) at baseline and weeks 4, 8 and 12. Patients were monitored for adverse drug reactions (ADRs). Clinical outcomes were compared among various groups based on gender, type of depressive episode (first or recurrent episode) and baseline HDRS-17 scores (moderate depression—score between 17 and 23; severe depression—score ≥ 24).

Results

Among the 148 subjects who completed the 12-week study, 43.9% and 42.6% achieved response and remission, respectively. The decline in HDRS-17 and MADRS scores from baseline was significant (p value < 0.05) at all follow-up visits and a similar pattern was seen with CGI. Efficacy outcomes were better in the moderate baseline depression group compared with severe depression. There were no associations of efficacy with gender and type of depressive episode. A total of 247 adverse drug reactions (ADR) were reported and 119 (80.41%) subjects experienced at least one ADR during the study period. No serious ADR was reported. Male patients experienced more ADRs compared with females. The safety profile of escitalopram was similar across various groups based on baseline depression severity and type of depressive episode.

Conclusion

The study revealed that escitalopram is efficacious in south Indian MDD patients with a favourable safety profile. The efficacy was influenced by baseline depression severity whereas more ADRs were reported by male patients.

World Health Report 2004: changing history. WHO; 2004.

Arvind BA, Gururaj G, Loganathan S, Amudhan S, Varghese M, Benegal V, et al. Prevalence and socioeconomic impact of depressive disorders in India: Multisite population-based cross-sectional study. BMJ Open. 2019;9(6):e027250. https://doi.org/10.1136/bmjopen-2018-027250.CrossRefPubMedPubMedCentral

Dhar AK, Barton DA. Depression and the link with cardiovascular disease. Front Psychiatry. 2016;7(MAR):1.

Xin LM, Chen L, Su YA, Yang FD, Wang G, Fang YR, et al. Risk factors for recent suicide attempts in major depressive disorder patients in China: results from a National Study. Front Psychiatry. 2018;9:300. https://doi.org/10.3389/fpsyt.2018.00300.CrossRefPubMedPubMedCentral

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):2011–30.CrossRef

Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet. 1997;32(Suppl 1):1–21.CrossRef

Anderson IM, Ferrier IN, Baldwin RC, Cowen PJ, Howard L, Lewis G, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343–96. https://doi.org/10.1177/0269881107088441.CrossRefPubMed

Lalit V, Appaya PM, Hegde RP, Mital AK, Mittal S, Nagpal R, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar major depression. Indian J Psychiatry. 2004;46(4):333–41.PubMedPubMedCentral

Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2012;6:853–61. https://doi.org/10.2147/PPA.S22495.CrossRefPubMedPubMedCentral

10.

Boulenger JP, Huusom AKT, Florea I, Bæmadraskdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006;22(7):1331–41. https://doi.org/10.1185/030079906X115513.CrossRefPubMed

11.

Jiang K, Li L, Wang X, Fang M, Shi J, Cao Q, et al. Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: A 24-week, open-label, prospective study in Chinese population. Neuropsychiatr Dis Treat. 2017;13:515–26. https://doi.org/10.2147/NDT.S120190.CrossRefPubMedPubMedCentral

12.

Grover S, Avasth A, Kalita K, Dalal P, Rao G, Chadda R, et al. IPS multicentric study: antidepressant prescription patterns. Indian J Psychiatry. 2013;55(1):41–5. https://doi.org/10.4103/0019-5545.105503.CrossRefPubMedPubMedCentral

13.

Steimer W. Pharmacogenetics and psychoactive drug therapy: ready for the patient? Ther Drug Monit. 2010;32(4):381–6. https://doi.org/10.1097/FTD.0b013e3181e1a78d.CrossRefPubMed

14.

Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649–59. https://doi.org/10.1016/S0006-3223(03)00231-2.CrossRefPubMed

15.

Balestri M, Calati R, Souery D, Kautzky A, Kasper S, Montgomery S, et al. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord. 2016;189:224–32. https://doi.org/10.1016/j.jad.2015.09.033.CrossRefPubMed

16.

Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry. 2007;68(7):1062–70. https://doi.org/10.4088/JCP.v68n0713.CrossRefPubMed

17.

Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. J Am Med Assoc. 2002;288(11):1403–9. https://doi.org/10.1001/jama.288.11.1403.CrossRef

18.

Masand PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003;25(8):2289–304. https://doi.org/10.1016/S0149-2918(03)80220-5.CrossRefPubMed

19.

Bennabi D, Aouizerate B, El-Hage W, Doumy O, Moliere F, Courtet P, et al. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 2015;171:137–41. https://doi.org/10.1016/j.jad.2014.09.020.CrossRefPubMed

20.

Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R, Serretti A. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci. 2011;36(2):87–113. https://doi.org/10.1503/jpn.100059.CrossRefPubMedPubMedCentral

21.

Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr. 2008;13(12):1066–86. https://doi.org/10.1017/S1092852900017120.CrossRefPubMed

22.

Locher C, Kossowsky J, Gaab J, Kirsch I, Bain P, Krummenacher P. Moderation of antidepressant and placebo outcomes by baseline severity in late-life depression: A systematic review and meta-analysis. J Affect Disord. 2015;181:50–60. https://doi.org/10.1016/j.jad.2015.03.062.CrossRefPubMed

23.

Association AP. Association, AP Diagnostic and statistical manual of mental disorders. 1995.

24.

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45. https://doi.org/10.1038/clpt.1981.154.CrossRefPubMed

25.

Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–32.PubMed

26.

Patel M, Patel V, Tiwari D, Shah VR, Patel D, Chanpa N. Efficacy and safety of escitalopram in first episode of major depressive disorder - a tertiary care Indian center experience. J Depress anxiety. 2018;7:1–5.CrossRef

27.

Pinto C, Trivedi JK, Vankar GK, Sharma PS, Narasimha V. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder. J Indian Med Assoc. 2007;105(7):364–8.PubMed

28.

Mao PX, Tang YL, Jiang F, Shu L, Gu X, Li M, et al. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. Depress Anxiety. 2008;25(1):46–54. https://doi.org/10.1002/da.20222.CrossRefPubMed

29.

Li G, Shen Y, Luo J, Li H. Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: a pooled analysis of 4 Chinese clinical trials. Medicine. 2017;96(39):e8142. https://doi.org/10.1097/MD.0000000000008142.CrossRefPubMedPubMedCentral

30.

Colonna L, Andersen HF, Reines EH. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin. 2005;21(10):1659–68. https://doi.org/10.1185/030079905X65484.CrossRefPubMed

31.

Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2002;17(3):95–102. https://doi.org/10.1097/00004850-200205000-00001.CrossRefPubMed

32.

Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009;2:CD006532.

33.

Wade AG, Crawford GM, Yellowlees A. Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study. BMC Psychiatry. 2011;11(1):42. https://doi.org/10.1186/1471-244X-11-42.CrossRefPubMedPubMedCentral

34.

Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40. https://doi.org/10.1176/appi.ajp.163.1.28.CrossRefPubMed

35.

Joffe RT, Young LT, Levitt AJ, MacQueen G, Marriott MJ, Robb J. Number of episodes and antidepressant response in major depression. Int J Neuropsychopharmacol. 1999;2(2):111–3. https://doi.org/10.1017/S1461145799001443.CrossRefPubMed

36.

Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report. Am J Psychiatry. 2008;165(3):342–51. https://doi.org/10.1176/appi.ajp.2007.06111868.CrossRefPubMed

37.

Mulder RT, Watkins WGA, Joyce PR, Luty SE. Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Disord. 2003;76(1–3):143–9. https://doi.org/10.1016/S0165-0327(02)00083-6.CrossRefPubMed

38.

Lopez-Castroman J, Jaussent I, Gorwood P, Courtet P. Suicidal depressed patients respond less well to antidepressants in the short term. Depress Anxiety. 2016;33(6):483–94. https://doi.org/10.1002/da.22473.CrossRefPubMed

39.

Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ. 2005;330(7488):396. https://doi.org/10.1136/bmj.330.7488.396.CrossRefPubMedPubMedCentral

40.

Isacsson G, Rich CL, Jureidini J, Raven M. The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. Br J Psychiatry. 2010;196(6):429–33. https://doi.org/10.1192/bjp.bp.109.076166.CrossRefPubMed

41.

Griffiths JJ, Zarate CA Jr, Rasimas JJ. Existing and novel biological therapeutics in suicide prevention. Am J Prev Med. 2014;47(3 Suppl 2):S195–203. https://doi.org/10.1016/j.amepre.2014.06.012.CrossRefPubMedPubMedCentral

42.

Ozdilek B. Escitalopram-induced bradycardia in elderly individuals: a case series report. Klin Psikofarmakol Bul. 2015;25(2):183–5. https://doi.org/10.5455/bcp.20140304090654.CrossRef

43.

Thase ME, Larsen KG, Reines E, Kennedy SH. The cardiovascular safety profile of escitalopram. Eur Neuropsychopharmacol. 2013;23(11):1391–400. https://doi.org/10.1016/j.euroneuro.2013.05.011.CrossRefPubMed

44.

Shinde M, Reddy P, Kulmi M, Goyal C. Efficacy and tolerability of milnacipran and escitalopram: a comparative study among patients of depression. Int J Basic Clin Pharmacol. 2018;7(5):839. https://doi.org/10.18203/2319-2003.ijbcp20181489.CrossRef

45.

Sánchez C, Bergqvist PBF, Brennum LT, Gupta S, Hogg S, Larsen A, et al. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003;167(4):353–62. https://doi.org/10.1007/s00213-002-1364-z.CrossRefPubMed

46.

Zhong H, Haddjeri N, Sánchez C. Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter--a review of current understanding of its mechanism of action. Psychopharmacology (Berl). 2012;219(1):1–13. https://doi.org/10.1007/s00213-011-2463-5.CrossRefPubMed

47.

Culpepper L. Escitalopram: A new SSRI for the treatment of depression in primary care. Prim Care Companion J Clin Psychiatry. 2002;4(6):209–14. https://doi.org/10.4088/PCC.v04n0601.CrossRefPubMedPubMedCentral

48.

Basu A, Chadda RK, Sood M, Kaur H, Kukreti R. A preliminary association study between serotonin transporter (5-HTTLPR), receptor polymorphisms (5-HTR1A, 5-HTR2A) and depression symptom-clusters in a north Indian population suffering from Major Depressive Disorder (MDD). Asian J Psychiatr. 2019;43:184–8. https://doi.org/10.1016/j.ajp.2019.05.028.CrossRefPubMed

49.

Mandal T, Bairy LK, Sharma PSVN. Association between functional polymorphisms in serotonin transporter gene (SLC6A4) and escitalopram treatment response in depressive patients in a South Indian population. Eur J of Clin Pharmacol. 2020;76(6):807–14. https://doi.org/10.1007/s00228-020-02866-4.CrossRef

50.

Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11(4):537–46. https://doi.org/10.2217/pgs.09.168.CrossRefPubMed

51.

Rajkumar R, Kashyap VK. Genetic structure of four socio-culturally diversified caste populations of southwest India and their affinity with related Indian and global groups. BMC Genet. 2004;5(1):23. https://doi.org/10.1186/1471-2156-5-23.CrossRefPubMedPubMedCentral

Title: Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India
Authors: Tatiyana Mandal
Laxminarayana Kurady Bairy
Podila Satya Venkata Narasimha Sharma
Vijaya Lakshmi Valaparla
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Escitalopram
Mood Disorders
Affective Disorder
Antidepressant Drugs
Antidepressant Drugs
Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery / Issue 1/2021
Electronic ISSN: 1687-8329
DOI: https://doi.org/10.1186/s41983-021-00302-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Impact of gender, depression severity and type of depressive episode on efficacy and safety of escitalopram: an observational study on major depressive disorder patients in southern India

Abstract

Background

Objectives

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Epidemiological profile of psychiatric illnesses in the province of Taza, Morocco: case of a study on a schizophrenic sub-population in the Ibn Baja Hospital

How COVID-19 pandemic changed our management strategies for amyotrophic lateral sclerosis (ALS) patients: Egyptian study

Neurological sequelae of COVID-19: a review

Migraine prevalence, clinical characteristics, and health care-seeking practice in a sample of medical students in Egypt

Reply to Letter to Editor: Is SARS-CoV-2 responsible for relapses of Parkinson’s disease?

Motor unit number estimation versus compound muscle action potential in the evaluation of motor unit loss in amyotrophic lateral sclerosis